|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
mood stabilizer
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N03AX09
|
|
gptkbp:bioavailability
|
98%
|
|
gptkbp:brand
|
gptkb:Lamictal
gptkb:Lamictal_XR
|
|
gptkbp:CASNumber
|
84057-84-1
|
|
gptkbp:chemicalClass
|
phenyltriazine
|
|
gptkbp:chemicalFormula
|
C9H7Cl2N5
|
|
gptkbp:contraindication
|
hypersensitivity to lamotrigine
|
|
gptkbp:discoveredBy
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
25 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
1980
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lamotrigine
|
|
gptkbp:interactsWith
|
gptkb:phenytoin
gptkb:valproic_acid
gptkb:carbamazepine
phenobarbital
oral contraceptives
primidone
|
|
gptkbp:IUPACName
|
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks voltage-gated sodium channels
inhibits glutamate release
|
|
gptkbp:meltingPoint
|
216°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:pregnancyRisk
|
may increase risk of cleft lip/palate
|
|
gptkbp:proteinBinding
|
55%
|
|
gptkbp:PubChem_CID
|
3878
DB00555
|
|
gptkbp:routeOfAdministration
|
oral
chewable tablet
dispersible tablet
|
|
gptkbp:sideEffect
|
gptkb:toxic_epidermal_necrolysis
gptkb:Stevens-Johnson_syndrome
nausea
dizziness
headache
blurred vision
rash
insomnia
|
|
gptkbp:solubility
|
slightly soluble
|
|
gptkbp:UNII
|
9JL9F0HLZ7
|
|
gptkbp:usedFor
|
bipolar disorder
epilepsy
seizure disorders
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Anticonvulsants
|
|
gptkbp:bfsLayer
|
7
|